H5N1) in northern Vietnam, 2004?005. Emerg Infect Dis 2009, 15:19?3. four. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA: Lowered sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis 2007, 13:1354?357. 5. Deyde VM, Xu X, Vibrant RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI: Surveillance of resistance to adamantanes amongst influenza A(H3N2) along with a(H1N1) viruses isolated worldwide. J Infect Dis 2007, 196:249?57. six. Hampson AW: Vaccines for pandemic influenza. The history of our existing vaccines, their limitations and the needs to handle a pandemic threat. Ann Acad Med Singapore 2008, 37:510?17. 7. Kieny MP, Fukuda K: The pandemic influenza vaccine challenge. Vaccine 2008, 26(Suppl 4):D3 4. 8. Sugrue RJ, Tan BH, Yeo DS, Sutejo R: Antiviral drugs for the handle of pandemic influenza virus. Ann Acad Med Singapore 2008, 37:518?24. 9. van der Vries E, van den Berg B, Schutten M: Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008, 359:1074?076. 10. Michaelis M, Doerr HW, Cinatl J Jr: Of chickens and guys: avian influenza in humans. Curr Mol Med 2009, 9:131?51. 11. Moscona A: Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009, 360:953?56. 12. Bavagnoli L, Maga G: The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. Curr Med Chem 2011, 18:5466?475. 13. Salter A, Ni LB, Crowley B: Emergence and phylogenetic analysis of amantadine-resistant influenza a subtype H3N2 viruses in Dublin, Ireland, over Six Seasons from 2003/2004 to 2008/2009. Intervirology 2011, 54:305?15.14. Harborne JB, Williams CA: Advances in flavonoid study due to the fact 1992. Phytochemistry 2000, 55:481?04. 15. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA: Flavonoids: a evaluation of probable mechanisms of action and possible applications. Am J Clin Nutr 2001, 74:418?25. 16. Kim Y, Narayanan S, Chang KO: Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res 2010, 88:227?35. 17. Xu G, Dou J, Zhang L, Guo Q, Zhou C: Inhibitory effects of baicalein around the influenza virus in vivo is determined by baicalin inside the serum.Fmoc-L-Val-OH uses Biol Pharm Bull 2010, 33:238?43.2,2′-Dipyridyl disulfide Formula 18.PMID:23329650 Chen L, Dou J, Su Z, Zhou H, Wang H, Zhou W, Guo Q, Zhou C: Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2011, 91:314?20. 19. Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM: Influenza neuraminidase: a druggable target for all-natural products. Nat Prod Rep 2012, 29:11?six. 20. Wang X, Jia W, Zhao A, Wang X: Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 2006, 20:335?41. 21. Liu AL, Wang HD, Lee SM, Wang YT, Du GH: Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 2008, 16:7141?147. 22. Song JM, Park KD, Lee KH, Byun YH, Park JH, Kim SH, Kim JH, Seong BL: Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res 2007, 76:178?85. 23. Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I: Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free of charge radical scavenging activity. Antioxid Redox Signal 2005, 7:32?1. 24. Hecht SS, Huang C, Stoner GD, Li J, Kenney PM, St.